Xbrane Biopharma AB Stock price

Equities

XBRANE

SE0007789409

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 07:59:52 2024-03-28 am EDT 5-day change 1st Jan Change
0.3015 SEK +3.97% Intraday chart for Xbrane Biopharma AB -39.40% -96.98%
Sales 2023 239M 22.35M Sales 2024 * 372M 34.82M Capitalization 8.65M 809K
Net income 2023 -388M -36.32M Net income 2024 * -101M -9.45M EV / Sales 2023 1.25 x
Net Debt 2023 * 164M 15.31M Net cash position 2024 * 138M 12.96M EV / Sales 2024 * -0.35 x
P/E ratio 2023
-0.74 x
P/E ratio 2024 *
-2.9 x
Employees 93
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.23%
More Fundamentals * Assessed data
Dynamic Chart
1 day+5.69%
1 week-51.43%
Current month-60.14%
1 month-45.27%
3 months-96.78%
6 months-98.86%
Current year-96.94%
More quotes
1 week
0.24
Extreme 0.238
0.61
1 month
0.24
Extreme 0.238
1.99
Current year
0.24
Extreme 0.238
10.84
1 year
0.24
Extreme 0.238
104.20
3 years
0.24
Extreme 0.238
180.40
5 years
0.24
Extreme 0.238
180.40
10 years
0.24
Extreme 0.238
180.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 44 14-12-31
Director of Finance/CFO 63 21-01-10
Chief Tech/Sci/R&D Officer 42 17-10-08
Members of the board TitleAgeSince
Director/Board Member 67 14-12-31
Director/Board Member 70 14-12-31
Director/Board Member 53 19-12-31
More insiders
Date Price Change Volume
24-03-28 0.3015 +3.97% 42 905 004
24-03-27 0.29 +11.54% 42,937,050
24-03-26 0.26 -2.07% 30,914,020
24-03-25 0.2655 -46.47% 89,924,220
24-03-22 0.496 -21.39% 14,555,870

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:21 am EDT

More quotes
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.29 SEK
Average target price
61.38 SEK
Spread / Average Target
+21,063.79%
Consensus
  1. Stock
  2. Equities
  3. Stock Xbrane Biopharma AB - Nasdaq Stockholm